• Linkedin
  • Twitter
  • Youtube
  • Facebook
  • Instagram
HCS Pharma
  • Company
    • About us
    • Team
    • Scientific Advisory Board
    • Advisory Board
    • Investors Relations
    • R&D programs and partnerships
      • BioPharMEMS
      • MIMLIVEROnChip
      • Nanostem
      • NEUROCELL3D
      • ONCO3D
      • RHU CHOPIN
      • ScaLABle-MEAT
      • VisuAI
    • Pressroom
      • Press releases
      • Photos for the press
      • HCS Pharma in press
    • Customer testimonials
    • Labels, prizes and distinctions
    • Partners and Memberships
    • Careers
    • Privacy Policy
  • BIOMIMESYS®
    • What is BIOMIMESYS® hydroscaffold?
    • BIOMIMESYS® Brain
    • BIOMIMESYS® Liver
    • BIOMIMESYS® Adipose tissue
    • BIOMIMESYS® Oncology
    • BIOMIMESYS® Custom
    • How to buy BIOMIMESYS®?
  • Support
    • BIOMIMESYS® Custom
    • Dermocosmetology
      • Anti-Aging
      • Anti-Oxidant
      • Anti-Redness
      • Wound Healing
      • Skin Pigmentation
      • Anti-Pollution
      • Skin Microbiota
      • Cosmetics custom developments
    • Pharmacology
      • Parkinson
      • Alzheimer
      • Migration
      • Cell cycle arrest
  • Ressources
    • Publications – Scientific articles
    • Application Notes
    • Conferences & Webinars
    • News
    • Posters
    • Brochures
    • BIOMIMESYS® tutorials
    • Customer testimonials
    • Certificate of Analyse
    • TDS&MSDS
    • Protocols
    • Frequently Asked Questions
  • Contacts
    • How to contact us?
    • How to buy BIOMIMESYS®?
    • Subscribe to our Newsletter

genotoxicity

News

To be genotoxic, or not? That is the question!

Distinguishing aneugenic (chromosomes loss) from clastogenic effects (DNA damages) is essential to assess genotoxic properties of compounds. In order to help you taking the right decisions for your compounds, we developed a multiplex assay in order to discriminate aneugenic from clastogenic and cytotoxic effects of your compounds in one single Read more…

By Pierre Jean Ferron, 5 yearsMarch 6, 2018 ago
News

See you next week on BioFIT 2017 event in Strasbourg!

Come and discover our programs on iPS and 3D culture

By Nathalie MAUBON, 5 yearsNovember 22, 2017 ago
News

We were at “HCS plateforms day” of the the French Agency For Food and Safety

Last friday (10/11), we presented our neurotoxicity and genotoxicity assays at the French Agency for Food and Safety (ANSES)

By Pierre Jean Ferron, 5 yearsNovember 20, 2017 ago
News

Our feedback of the 35th symposium of the French society of genetic toxicology in Marseille

We saw and participated to very interested sessions about genotoxic and epigenetic effects of environmental compounds

By Grégory MAUBON, 5 yearsNovember 7, 2017 ago
Posters

Poster – Use of Automated High Content Analysis or Imaging Applied To Assessment Of Primary DNA Damage With γH2AX and Comet Assays on different Cell types

Genotoxicity potential assessment of pharmaceuticals is mandatory for registration. In addition to the standard in vitro/ in vivo test battery, other assays can be of interest because of their high throughput in the drug discovery stage but also for mechanistic understanding.

By Grégory MAUBON, 6 yearsNovember 4, 2016 ago
News

Last day in Cosm’ing 2016

If you are in Cosm’ing meeting, don’t hesitate to go and discuss with Julian BURSZTYKA, our COO

By Nathalie MAUBON, 7 yearsJuly 1, 2016 ago
HCSPharma-Galderma
News

Genotoxicity assay development in collaboration with Galderma R&D

During ELRIGfr event in Rennes, We had the opportunity to present our work on genotoxicity assay (comet assay on TK6 & gH2AX on keratinocytes and HepG2) in collaboration with the team of in vitro of Galderma R&D. It is really exciting to work with them since they are really experts Read more…

By Nathalie MAUBON, 7 yearsJune 7, 2016 ago
Posters

Poster – Development of an Automated Comet Assay for Genotoxicity Assessment on TK6 cell line

Quantifying DNA damage is mandatory to assess potential adverse effects of candidate drugs or molecules or extracts developed in the dermo-cosmetic industry, but also to assess the efficacy of therapeutic approaches with the aim of producing tumor cell genotoxicity in cancer treatment.

By Nathalie MAUBON, 7 yearsMay 11, 2016 ago
News

Our feedback of lab automation congress of ELRIGfr in Bruxelles

I was present at the last congress ELRIGfr in Brussels. It was a strong exchange place with interesting presentations around robotics. It is always really interesting to see examples of innovative automation which give really robust results.

By Nathalie MAUBON, 7 yearsNovember 17, 2015 ago
Posters

Poster – Genotoxicity assays: assessment of double strand breaks through phospho-H2AX detection and micronuclei analysis in high content screening

Download our poster

By Grégory MAUBON, 7 yearsOctober 14, 2015 ago
News

HCS Pharma presented two posters at ELRIGfr during forum labo 2015

Nathalie and Julian were present during ELRIGfr event last week. They presented their company, their work and their collaborations. They have also presented two posters, one on co-culture model of Parkinson and first results in 3D dimension, and the other one, on genotoxicity and steatosis assay on HepG2 cells.

By Nathalie MAUBON, 8 yearsApril 7, 2015 ago
Posters

Poster – HepG2 cell model for genotoxicity and steatosis assessment

Download our poster

By Grégory MAUBON, 8 yearsMarch 27, 2015 ago
Clic to get more information

BIOMIMESYS®

Contacts
Contact us with this form!
Or
+33 769 999 137

Newsletter

Recent Posts
  • New 3D in vitro model of dysbiosis-induced colon cancer thanks to France Relance Plan
  • Retrospective HCS Pharma 2022
  • Animal tests no longer necessary before drug clinical trials? Let’s make it in 3D in preclinical studies… and with the extracellular matrix!
  • Tokyo Future Style Taiwan presented our BIOMIMESYS® products during Taiwan Healthcare Expo 2022
  • We were in Cosmet’Agora last week !
We talk about …
3D 3D cell culture 3D culture BIOMIMESYS BIOMIMESYS Brain blood brain barrier brain cancer cell congress cosmetology dermocosmetology drug ECM ELRIG event extracellular matrix genotoxicity HCS hcs pharma High content screening hyaluronic acid hydroscaffold imaging innovation in vitro in vitro models liver meeting Microbiota microscopy Molecular Devices NEUROCELL3D neurons neurotoxicity oncology organoids Parkinson phenotypic screening picture presentation screening skin toxicology webinar
  • Company
  • BIOMIMESYS®
  • Support
  • Ressources
  • Contacts
HCS Pharma (c) 2021 | Hestia | Powered by WordPress
 

Loading Comments...